Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...

Sodexo’s GPO, Entegra, has achieved comparable scale with Compass, increasing the likelihood it can close the margin gap in the near future.